|
The following table summarizes the royalty and commercial payment receivable activities during the years ended December 31, 2023 and 2022 (in thousands):
|
|
|
|
|
|
|
|
Short-Term |
Long-Term |
Balance as of January 1, 2022 |
|
$ |
— |
$ |
69,075 |
Receipt of royalty and commercial payments: |
|
|
|
|
|
Kuros |
|
|
— |
|
(2,500) |
Affitech |
|
|
— |
|
(526) |
Reclassification to short-term royalty and commercial payment receivable |
|
|
|
|
|
Affitech |
|
|
2,366 |
|
(2,366) |
Balance as of December 31, 2022 |
|
$ |
2,366 |
$ |
63,683 |
Acquisition of royalty and commercial payment receivables: |
|
|
|
|
|
Aptevo |
|
|
— |
|
9,650 |
LadRx |
|
|
— |
|
6,000 |
Receipt of royalty and commercial payments: |
|
|
|
|
|
Affitech |
|
|
(7,284) |
|
— |
Aptevo |
|
|
— |
|
(1,673) |
Viracta |
|
|
|
|
(5,000) |
Impairment of royalty and commercial payment receivables: |
|
|
|
|
|
Bioasis |
|
|
— |
|
(1,575) |
Reclassification to short-term royalty and commercial payment receivables: |
|
|
|
|
|
Affitech |
|
|
17,109 |
|
(17,109) |
Aptevo |
|
|
2,024 |
|
(2,024) |
Recognition of contingent consideration: |
|
|
|
|
|
Affitech |
|
|
— |
|
6,000 |
Balance as of December 31, 2023 |
|
$ |
14,215 |
$ |
57,952 |
|